

---

# 5.90.068

---

<b>Section:</b>	Prescription Drugs	<b>Effective Date:</b>	April 1, 2026
<b>Subsection:</b>	Biologicals	<b>Original Policy Date:</b>	November 24, 2023
<b>Subject:</b>	OmvoH	<b>Page:</b>	1 of 9

---

**Last Review Date:** March 6, 2026

---

## OmvoH

### Description

#### OmvoH (mirikizumab-mrkz)

#### Background

OmvoH (mirikizumab-mrkz) is a humanized IgG4 monoclonal antibody that selectively binds to the p19 subunit of human interleukin (IL)-23 cytokine and inhibits its interaction with the IL-23 receptor. IL-23 is involved in mucosal inflammation and affects the differentiation, expansion, and survival of T cell subsets, and innate immune cell subsets, which represent sources of pro-inflammatory cytokines. Research in animal models has shown that pharmacological inhibition of IL-23p19 can ameliorate intestinal inflammation. OmvoH inhibits the release of pro-inflammatory cytokines and chemokines (1).

#### Regulatory Status

FDA-approved indication: OmvoH is an interleukin-23 antagonist indicated for the treatment of:  
(1)

- moderately to severely active ulcerative colitis (UC) in adults.
- moderately to severely active Crohn's disease in adults.

OmvoH may increase the risk of infections. OmvoH should not be given to patients with any clinically important active infection until the infection resolves or is adequately treated. If a serious infection develops or an infection is not responding to standard therapy, monitor the patient closely and do not administer OmvoH until the infection resolves (1).

---

<b>Section:</b>	Prescription Drugs	<b>Effective Date:</b>	April 1, 2026
<b>Subsection:</b>	Biologicals	<b>Original Policy Date:</b>	November 24, 2023
<b>Subject:</b>	OmvoH	<b>Page:</b>	2 of 9

---

Evaluate patients for tuberculosis infection prior to initiating treatment with OmvoH. Do not administer OmvoH to patients with active tuberculosis. Initiate treatment of latent tuberculosis prior to administering OmvoH. Consider anti-tuberculosis therapy prior to initiation of OmvoH in patients with a past history of latent or active tuberculosis in whom an adequate course of treatment cannot be confirmed. Patients receiving OmvoH should be monitored closely for signs and symptoms of active tuberculosis during and after treatment (1).

OmvoH may cause hepatotoxicity. Liver enzymes and bilirubin should be evaluated at baseline and for at least 24 weeks of treatment. Consider other treatment options in patients with evidence of liver cirrhosis (1).

The safety and effectiveness of OmvoH in pediatric patients less than 18 years of age have not been established (1).

## Related policies

Ilumya, Skyrizi, Stelara, Tremfya

### Policy

*This policy statement applies to clinical review performed for pre-service (Prior Approval, Precertification, Advanced Benefit Determination, etc.) and/or post-service claims.*

OmvoH may be considered **medically necessary** if the conditions indicated below are met.

OmvoH may be considered **investigational** for all other indications.

## Prior-Approval Requirements

**Age** 18 years of age or older

### Diagnoses

Patient must have **ONE** of the following with provided documentation (e.g., medical records, laboratory reports):

1. Moderate to severely active ulcerative colitis (UC)
  - a. Inadequate treatment response, intolerance, or contraindication to at least **ONE** conventional therapy option (see Appendix 1)

---

<b>Section:</b>	Prescription Drugs	<b>Effective Date:</b>	April 1, 2026
<b>Subsection:</b>	Biologicals	<b>Original Policy Date:</b>	November 24, 2023
<b>Subject:</b>	OmvoH	<b>Page:</b>	3 of 9

---

- b. Prescriber will initiate dosing with three 300 mg intravenous infusions
  - c. Prescriber will not exceed the FDA labeled maintenance dose of 200 mg SC every 4 weeks
  - d. Patient **MUST** have tried the preferred product(s) (see Appendix 3) if adjudicated through pharmacy benefit unless the patient has a valid medical exception (e.g., inadequate treatment response, intolerance, contraindication)
2. Moderately to severely active Crohn's disease (CD)
- a. Inadequate treatment response, intolerance, or contraindication to at least **ONE** conventional therapy option (see Appendix 1)
  - b. Prescriber will initiate dosing with three 900 mg intravenous infusions
  - c. Prescriber will not exceed the FDA labeled maintenance dose of 300 mg SC every 4 weeks
  - d. Patient **MUST** have tried the preferred product(s) (see Appendix 3) if adjudicated through the pharmacy benefit unless the patient has a valid medical exception (e.g., inadequate treatment response, intolerance, contraindication)

**AND ALL** of the following:

- 1. Result for latent TB infection is negative **OR** result was positive for latent TB and patient completed treatment (or is receiving treatment) for latent TB
- 2. Absence of active infection [including tuberculosis and hepatitis B virus (HBV)]
- 3. **NOT** to be used in combination with any other biologic DMARD or targeted synthetic DMARD (see Appendix 2)
- 4. **NOT** given concurrently with live vaccines

All approved requests are subject to review by a clinical specialist for final validation and coverage determination once all required documentation has been received. Current utilization, including samples, does not guarantee approval of coverage.

## **Prior – Approval *Renewal* Requirements**

**Age** 18 years of age or older

### **Diagnoses**

Patient must have **ONE** of the following with provided documentation (e.g., medical records, laboratory reports):

<b>Section:</b> Prescription Drugs	<b>Effective Date:</b> April 1, 2026
<b>Subsection:</b> Biologicals	<b>Original Policy Date:</b> November 24, 2023
<b>Subject:</b> Omvoh	<b>Page:</b> 4 of 9

1. Ulcerative colitis (UC)
  - a. Prescriber will not exceed the FDA labeled maintenance dose of 200 mg SC every 4 weeks
  - b. Patient **MUST** have tried the preferred product(s) (see Appendix 3) if adjudicated through pharmacy benefit unless the patient has a valid medical exception (e.g., inadequate treatment response, intolerance, contraindication)
2. Crohn's disease (CD)
  - a. Prescriber will not exceed the FDA labeled maintenance dose of 300 mg SC every 4 weeks
  - b. Patient **MUST** have tried the preferred product(s) (see Appendix 3) if adjudicated through the pharmacy benefit unless the patient has a valid medical exception (e.g., inadequate treatment response, intolerance, contraindication)

**AND ALL** of the following:

1. Condition has improved or stabilized with Omvoh
2. Absence of active infection [including tuberculosis and hepatitis B virus (HBV)]
3. **NOT** to be used in combination with any other biologic DMARD or targeted synthetic DMARD (see Appendix 2)
4. **NOT** given concurrently with live vaccines

All approved requests are subject to review by a clinical specialist for final validation and coverage determination once all required documentation has been received. Current utilization, including samples, does not guarantee approval of coverage.

## Policy Guidelines

### Pre - PA Allowance

None

### Prior - Approval Limits

#### Quantity

Diagnosis	Strength	Quantity
Crohn's disease (CD)	300 mg IV vial 100 mg SC pen/syringe 200 mg SC pen/syringe	9 IV vials (3 doses) + 6 SC pens/syringes per 84 days

<b>Section:</b>	Prescription Drugs	<b>Effective Date:</b>	April 1, 2026
<b>Subsection:</b>	Biologicals	<b>Original Policy Date:</b>	November 24, 2023
<b>Subject:</b>	OmvoH	<b>Page:</b>	5 of 9

Ulcerative colitis (UC)	300 mg IV vial 100 mg SC pen/syringe	3 IV vials (3 doses) + 6 SC pens/syringes per 84 days
-------------------------	---	--

**Duration** 12 months

## Prior – Approval *Renewal* Limits

### Quantity

Diagnosis	Strength	Quantity
Crohn's disease (CD)	100 mg SC pen/syringe	6 SC pens/syringes per 84 days
	200 mg SC pen/syringe	
Ulcerative colitis (UC)	100 mg SC pen/syringe	6 SC pens/syringes per 84 days

**Duration** 18 months

## Rationale

### Summary

OmvoH is an interleukin-23 antagonist indicated for the treatment of moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD) in adults. OmvoH has warnings regarding infections, tuberculosis, hepatotoxicity, and immunizations. The safety and effectiveness of OmvoH in pediatric patients less than 18 years of age have not been established (1).

Prior authorization is required to ensure the safe, clinically appropriate, and cost-effective use of OmvoH while maintaining optimal therapeutic outcomes.

### References

1. OmvoH [package insert]. Indianapolis, IN: Eli Lilly and Company; October 2025.

## Policy History

Date	Action
November 2023	Addition to PA
March 2024	Annual review
February 2025	Per PI update, added indication of CD
December 2025	Annual review. Added documentation requirement. Revised Appendix 3
March 2026	Annual review and reference update

# 5.90.068

---

**Section:** Prescription Drugs

**Effective Date:** April 1, 2026

**Subsection:** Biologicals

**Original Policy Date:** November 24, 2023

**Subject:** Omvoh

**Page:** 6 of 9

---

## Keywords

**This policy was approved by the FEP® Pharmacy and Medical Policy Committee on March 6, 2026 and is effective on April 1, 2026.**

<b>Section:</b>	Prescription Drugs	<b>Effective Date:</b>	April 1, 2026
<b>Subsection:</b>	Biologicals	<b>Original Policy Date:</b>	November 24, 2023
<b>Subject:</b>	OmvoH	<b>Page:</b>	7 of 9

### Appendix 1 – List of Conventional Therapies

Conventional Therapy Options for CD	
1. Mild to moderate disease – induction of remission:	a. Oral budesonide, oral mesalamine b. Alternatives: metronidazole, ciprofloxacin
2. Mild to moderate disease – maintenance of remission:	a. Azathioprine, mercaptopurine b. Alternatives: oral budesonide, methotrexate intramuscularly (IM)
3. Moderate to severe disease – induction of remission:	a. Prednisone, methylprednisolone intravenously (IV) b. Alternatives: methotrexate IM
4. Moderate to severe disease – maintenance of remission:	a. Azathioprine, mercaptopurine b. Alternative: methotrexate IM
5. Perianal and fistulizing disease – induction of remission	c. Metronidazole ± ciprofloxacin
6. Perianal and fistulizing disease – maintenance of remission	d. Azathioprine, mercaptopurine e. Alternative: methotrexate IM

Conventional Therapy Options for UC	
1. Mild to moderate disease – induction of remission:	a. Oral mesalamine (e.g., Asacol, Lialda, Pentasa), balsalazide, olsalazine b. Rectal mesalamine (e.g., Canasa, Rowasa) c. Rectal hydrocortisone (e.g., Colocort, Cortifoam) d. Alternatives: prednisone, azathioprine, mercaptopurine, sulfasalazine
2. Mild to moderate disease – maintenance of remission:	a. Oral mesalamine, balsalazide, olsalazine, rectal mesalamine b. Alternatives: azathioprine, mercaptopurine, sulfasalazine
3. Severe disease – induction of remission:	a. Prednisone, hydrocortisone IV, methylprednisolone IV b. Alternatives: cyclosporine IV, tacrolimus, sulfasalazine
4. Severe disease – maintenance of remission:	a. Azathioprine, mercaptopurine b. Alternative: sulfasalazine
5. Pouchitis:	a. Metronidazole, ciprofloxacin b. Alternative: rectal mesalamine

### Appendix 2 - List of DMARDs

#### Conventional disease-modifying antirheumatic drugs (DMARDs)

Generic Name	Brand Name
--------------	------------

**Section:** Prescription Drugs**Effective Date:**

April 1, 2026

**Subsection:** Biologicals**Original Policy Date:**

November 24, 2023

**Subject:** Omvoh**Page:**

8 of 9

azathioprine	Azasan, Imuran
cyclophosphamide	Cytoxan
cyclosporine	Neoral, Gengraf, Sandimmune
hydroxychloroquine	Plaquenil
leflunomide	Arava
methotrexate	Rheumatrex, Trexall
mycophenolate	Cellcept
sulfasalazine	Azulfidine, Sulfazine

**Biological disease-modifying antirheumatic drugs (DMARDs)**

Generic Name	Brand Name
abatacept	Orencia
adalimumab	Humira
anakinra	Kineret
brodalumab	Siliq
certolizumab	Cimzia
etanercept	Enbrel
golimumab	Simponi/Simponi Aria
guselkumab	Tremfya
infliximab	Remicade
ixekizumab	Taltz
mirikizumab-mrkz	Omvoh
risankizumab-rzaa	Skyrizi
rituximab	Rituxan
sarilumab	Kevzara
secukinumab	Cosentyx
spesolimab-sbzo	Spevigo
tildrakizumab-asmn	Ilumya
tocilizumab	Actemra
ustekinumab	Stelara
vedolizumab	Entyvio

**Targeted synthetic disease-modifying antirheumatic drugs (DMARDs)**

Generic Name	Brand Name
apremilast	Otezla
baricitinib	Olumiant
deucravacitinib	Sotyktu
tofacitinib	Xeljanz/XR

**Section:** Prescription Drugs

**Effective Date:** April 1, 2026

**Subsection:** Biologicals

**Original Policy Date:** November 24, 2023

**Subject:** Omvoh

**Page:** 9 of 9

---

upadactinib	Rinvoq
-------------	--------

### **Appendix 3 - List of Preferred Products**

List of preferred products:

[https://info.caremark.com/content/dam/enterprise/caremark/microsites/dig/pdfs/pa-fep/fep-misc/FEP\\_IndicationMedChx.pdf](https://info.caremark.com/content/dam/enterprise/caremark/microsites/dig/pdfs/pa-fep/fep-misc/FEP_IndicationMedChx.pdf)

Refer to formulary documents for confirmation of coverage:

<https://www.fepblue.org/pharmacy/prescriptions#drug-lists>